

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. **(Previously Presented)** A compound selected from the group consisting of:
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-[3-nitro-phenyl]-amine [1];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-[4-trifluoromethyl-phenyl]-amine [7];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-[4-methoxy-phenyl]-amine [8];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-[3-chloro-phenyl]-amine [9];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-[3-iodo-phenyl]-amine [10];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-[4-iodo-phenyl]-amine [11];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-[4-fluoro-phenyl]-amine [12];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-[3-bromo-phenyl]-amine [16];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-[4-bromo-phenyl]-amine [17];
N-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-methanesulfonamide [56];
2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol [58];
2-{5-[2-(4-Fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-ylamino}-ethanol [59];
2-Chloro-N-{4-methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-acetamide [60];
2-Chloro-N-{5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-acetamide [61];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-[4-nitro-phenyl]-amine [63];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-[phenyl]-amine [64]; and
4-[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-benzenesulfonic acid [65]; or a pharmaceutically acceptable salt thereof.

2. **(Previously Presented)** A compound according to claim 1, selected from the group consisting of:

[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-[3-nitro-phenyl]-amine [1];

[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-chloro-phenyl)-amine [9];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-iodo-phenyl)-amine [10];
N-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-
methanesulfonamide [56];
2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol
[58];
2-Chloro-N-{4-methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-
acetamide [60]; and
2-Chloro-N-{5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-
acetamide [61], or a pharmaceutically acceptable salt thereof.

3. (Previously Presented) A compound according to claim 2, selected from the group consisting of:

2-Chloro-N-{4-methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-
acetamide [60]; and
2-Chloro-N-{5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-
acetamide [61], or a pharmaceutically acceptable salt thereof.

4. (Currently Amended) A compound according to claim 12, selected from the following:

[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-chloro-phenyl)-amine [9];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-iodo-phenyl)-amine [10];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-bromo-phenyl)-amine [16];
N-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-
methanesulfonamide [56]; and
2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol
[58] or a pharmaceutically acceptable salt thereof.

5. (Previously Presented) The compound of claim 4, wherein said compound is 2-{4-Methyl-5-[2-(3-nitro-phenyl amino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol [58] or a pharmaceutically acceptable salt thereof.

Claims 6-9 (Cancelled).

10. **(Currently Amended)** A compound according to claim 19 which is selected from the group consisting of:

[4-(2-amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1];
N-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-methanesulfonamide [56]; and
2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol [58]; or a pharmaceutically acceptable salt thereof.

11. **(Currently Amended)** A compound according to claim 19 which is [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1]; or a pharmaceutically acceptable salt thereof.

12. **(Currently Amended)** A pharmaceutical composition comprising a compound according to claim 1 ~~or 6~~, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent, excipient or carrier.

13. **(Original)** A pharmaceutical composition according to claim 12 which further comprises one or more other anticancer agents.

14. **(Currently Amended)** A method for treating a CDK-sensitive or CDK-dependent proliferative disorder in a subject, comprising administering one or more compound of claim 1 ~~or 6~~, or a pharmaceutically acceptable salt thereof, to a subject, such that the subject is treated for a proliferative disorder.

15. **(Original)** The method of claim 14, wherein the proliferative disorder is cancer or leukaemia.

Claim 16 **(Cancelled)**.

17. **(Currently Amended)** The method of claim 14~~16~~ wherein the CDK enzyme is said one or more compounds are administered in an amount sufficient to inhibit CDK2 or CDK4.

18. **(Cancelled)**.

19. **(Previously Presented)** The method of claim 14, wherein said compound is administered in combination with one or more other anticancer agents.
20. **(Previously Presented)** The method of claim 14, wherein said proliferative disorder is lung cancer.
21. **(Previously Presented)** The method of claim 14, wherein said proliferative disorder is colon cancer.
22. **(Previously Presented)** The method of claim 14, wherein said proliferative disorder is bone cancer.